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1Center for Rheumatology and Spine Diseases, Institute for Inflammation Research, Copenhagen University Hospital,
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Background: Microvesicles (MVs) expressing the type 1 interferon (IFN)-inducible
protein galectin-3 binding protein (G3BP) may play a pathogenic role in systemic lupus
erythematosus (SLE). Co-expression of double-stranded DNA (dsDNA) on such MVs
may render them immunogenic and targets for anti-dsDNA antibodies. Little is known
about the mechanisms underlying generation of this MV population. In this study, we
investigated how Toll-like receptors (TLRs), IFN-α, and T cells are involved in this process
in healthy subjects.
Methods: Peripheral bloodmononuclear cells (PBMCs) isolated from 12 healthy donors
were stimulated in-vitro for 24 h with a series of TLR-agonists or the T cell activating
antibody OKT3 or were subjected to apoptosis by incubation with staurosporine.
MVs in the supernatants were subsequently isolated by differential centrifugation and
were quantified and characterized with respect to expression of G3BP and dsDNA by
flow cytometry.
Results: Stimulation of PBMCs with the TLR9-agonist and strong IFN-α inducer
ODN2395 significantly increased the release of MVs expressing G3BP. The production
of MVs with this phenotype was markedly enhanced by co-stimulation of T cells.
Furthermore, dependency on IFN-α in the generation of G3BP-expressing MVs
was indicated by a marked reduction following addition of the IFN-α inhibitor
IFN alpha-IFNAR-IN-1 hydrochloride.
Conclusion: Release of G3BP-expressing MVs from healthy donor PBMCs is induced
by stimulation of TLR9 in an IFN-α-dependent manner and is enhanced by co-stimulation
of T cells.
Keywords: peripheral blood mononuclear cells, T cells, microvesicles, Toll-like receptor 9 agonist, type 1
interferon, galectin-3 binding protein, dsDNA, systemic lupus erythematosus
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BACKGROUND
Extracellular vesicles (EVs) are double-layered membrane
vesicles that may be released by cells in response to activation or
during apoptosis (1, 2). Accumulating evidence shows that EVs
are not inert, but usually carry an orchestrated cargo of proteins
and nucleic acids with diverse physiological roles in health and
disease (3, 4). These include diverse paracrine functions, with
extracellular RNAs playing a central role (5), but it is recognized
that also other mechanisms should be explored (6). There is a
growing interest and understanding of the role of EVs in the
context of systemic autoimmune disease, in particular systemic
lupus erythematosus (SLE) (7).
EV studies in SLE have mainly focused on so-called
microparticles that comprise 0.1–1µm microvesicles (MVs)
and the somewhat larger apoptotic bodies (8). SLE MVs
carry double-stranded DNA (dsDNA), whereby they may
become targets for binding of anti-dsDNA antibodies (9).
Proteomics show that circulating MVs from SLE patients hold
a characteristic signature of increased expression of galectin-3
binding protein (G3BP), immunoglobulin G (IgG), and several
other proteins (10, 11). Complementary to these findings are
flow cytometric analyses showing elevated blood levels of MVs
with surface-bound IgG (12) or G3BP (13) in SLE patients.
The origin and pathogenic relevance of this subset of MVs
remain obscure. However, defective removal of cellular remnants
and immune complexes (ICs) are well-established elements
of SLE pathogenesis (14), and specific roles of dsDNA-loaded
MVs in this context have been suggested (15, 16). In SLE
patients with nephritis, deposits of IgG in the glomerular
basement membrane (GBM) colocalize with chromatin
forming electron dense structures (EDS) (17) that also contain
G3BP (13).
G3BP is a type 1 interferon (IFN)-inducible protein that
belongs to the scavenger receptor cysteine-rich (SRCR)
superfamily (18) and binds to several components of the
GBM, including nidogen, collagen IV, and fibronectin
(19)–a property which, in theory, renders G3BP-expressing
MVs glomerulophilic.
The increased production of IFN-α frequently found in
SLE patients with active disease is thought to prime the
immune system toward breach of self-tolerance and persistent
autoimmune reactions and appears to be linked to Toll-like
receptor (TLR)7 and TLR9 ligation by nucleic acid-containing
ICs (20). The notion has been carried forward that ICs are
presented to the immune system in the context of chromatin-
loaded vesicles formed during apoptosis (16), but the role
of smaller MVs formed during cellular activation has not
been investigated.
Given that G3BP is type 1 IFN-inducible (21), we speculated
that MVs expressing dsDNA and G3BP may be released from
mononuclear cells as a result of TLR- and type 1 IFN-mediated
activation. Further, since activated T cells may enhance TLR-
mediated IFN-α production (22), T cells may play a particular
role in this type of MV generation.
In this study, we tap into this hypothesis by stimulating
peripheral blood mononuclear cells (PBMCs) from healthy
subjects with different TLR ligands, a T cell stimulator and a
type-1 IFN inhibitor to quantify the generation of dsDNA- and
G3BP-expressing MVs.
MATERIALS AND METHODS
Blood Donors
Blood from anonymous healthy donors was obtained from the
Blood Bank at Copenhagen University Hospital, Rigshospitalet.
The study was approved by the Scientific-Ethical Committee of
the Capital Region of Denmark (protocol no. H-15004075).
Isolation and Staining of Platelets
Three milliliter of blood was collected in Multiplate R© Hirudin
blood tubes (Roche Diagnostics GmbH, Mannheim, Germany)
by venous puncture. The blood was centrifuged at 1,800 × g
for 10min at 21◦C, platelet-rich plasma was carefully aspirated,
and 1mL was transferred to Eppendorf tubes (Corning, New
York City, USA) and centrifuged at 3,000 × g for 10min at
21◦C to pellet platelets. The platelet-poor plasma was carefully
aspirated and discarded, and platelets were gently resuspended
in 300 µL phosphate-buffered saline (PBS) (Thermo Fisher
Scientific, Waltham, USA) filtered through a 0.2µm filter
(Sartorius, Göttingen, Germany). Five microliter of the platelet-
isolate was pipetted into 37.5µL filtered PBS in FACS tubes
(Corning) followed by addition of 5 µL APC-conjugated anti-
CD61 antibody (BD, Franklin Lakes, USA) and 2.5 µL calcein-
acetoxymethyl ester (calcein-AM) (Sigma-Aldrich, St. Louis,
USA) (2.5µg/ml in filtered PBS) to a final volume of 50 µL. The
tubes were incubated for 1 h at room temperature (RT) in the
dark. After incubation, 100µL TruCount beads (BD) and 125 µL
Megamix-Plus side-scatter (SSC) beads (Biocytex, Marseille,
France) were added to the tubes. The volume was adjusted to
300µL with filtered PBS before analysis. The TruCount bead
solution was prepared by dissolving the lyophilized beads in
500µL filtered PBS. Samples were analyzed on a FACSCanto
II flow cytometer (BD) at low flow-rate and with lowest SSC
threshold (=200).
Isolation of PBMCs
Blood was collected in Vacutainer R© EDTA tubes (Greiner Bio-
one GmbH, Kremsmünster, Austria) by venous puncture and
centrifuged at 1,800 × g for 10min at 21◦C. Platelet-rich
plasma was aspirated, and the PBMCs were poured onto a
density gradient medium (LymphoprepTM; Alere Technologies,
Oslo, Norway), centrifuged at 1,172 × g for 30min at 24◦C,
washed twice in sterile PBS, and finally resuspended in sterile
medium consisting of RPMI-1640 GlutaMAX medium (Lonza,
Basel, Schweiz) supplemented with 20% heat-inactivated fetal
calf serum (hFCS) (Sigma-Aldrich) and 0.1% gentamicin (BI,
Kibbutz Beit Haemek, Israel). PBMCs were subsequently counted
using the NucleoCounter R© NC-100TM system (ChemoMetec,
Allerød, Denmark) according to the manufacturer’s instructions.
The PBMC-isolate was divided into 500 µL aliquots in cryotubes
(DACOS, Esbjerg, Denmark), followed by addition of 500
µL sterile medium supplemented with 30% hFCS and 20%
dimethylsulfoxid (DMSO) (Merck kGaA, Darmstadt, Germany),
yielding a final concentration of 25% hFCS and 10% DMSO. The
cryotubes were inverted, placed in CoolCell R© freezing containers
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(BioCision, San Rafael, USA), and stored at −80◦C for at least
24 h, before they were cryopreserved.
Stimulation of PBMCs
The cryopreserved PBMCs were thawed at RT, washed and
resuspended in sterile medium supplemented with 20% hFCS
(Sigma-Aldrich) and 0.1% gentamicin (BI). Their viability
was confirmed using the NucleoCounter R© NC-100TM system
according to the manufacturer’s instructions. The cells were
plated into 48-well plates with UpCellTM surface (Nunc,
Roskilde, Denmark) at ∼600,000 PBMCs per well and were
rested for 30min at 37◦C and 5% CO2 before incubation for
24 h at 37◦C and 5% CO2 with the following components
or combinations hereof: staurosporine for induction of
apoptosis (Abcam, Cambridge, UK) (2.5µM); the TLR3-agonist
poly(A:U) (Invivogen, San Diego, USA) (20µg/mL); the TLR4-
agonist lipopolysaccharide (LPS) (Invivogen) (1.25µg/mL);
the TLR7-agonist gardiquimod (Invivogen) (1.5µg/mL);
the TLR9-agonists ODN2006 (Invivogen) (12µg/mL) or
ODN2395 (Invivogen) (12µg/mL) (23); the inhibitor of the
interaction between IFN-α and the IFN-α receptor (IFNAR) IFN
alpha-IFNAR-IN-1 hydrochloride (IN-1) (MedchemExpress,
Sollentuna, Sweden) (32µM) (24); the T cell stimulating
anti-CD3 antibody OKT3 (Invitrogen, Carlsbad, USA)
(1µg/mL) (25).
Preparation of Culture Supernatants
After incubation with stimuli the plates were left at RT for 15min.
Adhered cells were gently loosened and transferred to FACS
tubes. The cell suspensions were centrifuged at 458× g for 10min
at 24◦C to pellet PBMCs. The cell-free supernatants were then
harvested, aliquoted into cryotubes, and snap-frozen in liquid
nitrogen. Samples were stored at−80◦C until analysis.
Isolation of MVs From Culture
Supernatants
The frozen cell-free supernatants were thawed at RT, transferred
to Eppendorf tubes, and centrifuged at 3,000 × g for 10min at
21◦C to pellet larger particles and potential cell residues. The
supernatants were aspirated down to 50 µL and transferred
to new tubes (200 µL in each). For some experiments, DNase
solution (Stemcell Technologies, Vancouver, Canada) was added
to the tubes to a final concentration of 0.1 mg/ml (∼200 U/mL)
and the tubes were then incubated for 1 h at 37◦C and 5% CO2.
The samples were ultracentrifuged at 20,000 × g for 30min
at 21◦C to pellet MVs. Subsequently, 175 µL supernatant was
aspirated and discarded, and MVs were then resuspended in
175 µL PBS filtered through 0.2µm pores, followed by another
ultracentrifugation step. The supernatant was aspirated as before
and discarded, and MVs were resuspended in 70 µL filtered PBS
to a final volume of 95 µL (MV-isolate).
Detection and Staining of MVs
We used calcein as a general marker of MVs (26). Any Fcγ-
receptors on MVs were blocked by adding 5 µL commercial
Fc blocker (BD) to MV-isolates for 15min at RT. After this
incubation, 5 µL MV-isolate was pipetted into 22.5 µL filtered
PBS in FACS tubes followed by addition of 5 µL mouse
anti-human G3BP antibody of IgG2b isotype (clone: 2D8E11)
(Proteintech, Manchester, UK) (1µg/mL in filtered PBS) or
isotype control (clone: MG2b-57) (Biolegend, San Diego, USA),
5 µL mouse anti-dsDNA antibody of IgG2a isotype (clone:
HYB 331-01) (SSI, Copenhagen, Denmark) (0.5µg/mL in filtered
PBS), or isotype control (clone: MG2a-53) (Biolegend). Next, 5
µL APC-conjugated goat anti-mouse IgG2b antibody (Southern
Biotech, Birmingham, USA) (0.5µg/mL in filtered PBS), 5
µL BV510-conjugated rat anti-mouse IgG2a antibody (BD)
(0.5µg/mL in filtered PBS), and 2.5 µL calcein-AM (2.5µg/mL
in filtered PBS) were added, yielding a final volume of 50 µL.
Unstained and single-stained controls were included. The tubes
were incubated for 1 h at RT in the dark. After incubation, 100µL
TruCount beads (BD) were added to the tubes and the volume
was adjusted to 300 µL with filtered PBS before acquisition on
a FACSCanto II flow cytometer (BD) at low flow-rate and with
lowest SSC threshold (=200). The TruCount bead solution was
prepared by dissolving the lyophilized beads in 500 µL filtered
PBS. Each sample was run for 4min or until a minimum of 1,000
TruCount bead events were recorded.
Quantification and Size Determination of
MVs
The absolute count of MVs (MVs/µL) was calculated with
TruCount beads as reference, using the formula:
[[(no. of MV events within gates of interest)/(no. of collected
bead events)] × [(total no. of beads)/(test volume)]] ×
(dilution factor).
Megamix-Plus SSC beads–a SSC optimized mixture of
polystyrene beads with size references of 0.16, 0.2, 0.24, and 0.5
µm–were utilized to define a SSC specified MV gate. Due to
the higher refractive index (RI) of polystyrene relative to that
of MVs (lipid vesicles), these size references are not directly
translatable, as described by van der Pol et al. and others
(27–30). To allow for such discrepancy, we estimated lipid
vesicle equivalents based on Mie theory (31–33) by taking the
RI of the particles and surrounding medium, the collection
angle of the scattered light, and the illumination wavelength
and intensity into account. All estimations were made with
the free software Mieplot (www.philiplaven.com/mieplot.htm).
The resulting plots (Supplementary Figure 1) depict that the
SSC light of 0.2 and 0.24µm polystyrene beads corresponds to
that of 0.5 and 1.0µm lipid vesicles, respectively, and the SSC
light of 0.5µm polystyrene beads corresponds to that of 2.7µm
lipid vesicles.
Transmission Electron Microscopy
MV-isolates were adsorbed onto carbon-coated grids for
1min. The excess liquid was removed with filter paper,
and the grids were then washed in double-distilled water
prior to staining with 3% uranyl acetate solution for 1min.
Using the principle of negative staining, the samples were
analyzed on a CM100 transmission electron microscope (Philips,
Eindhoven, Netherlands).
Statistical Analysis
Wilcoxon signed-rank test was used for comparisons of
concentrations and ratios between paired samples. In cases where
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FIGURE 1 | Microvesicle staining, gating, and quantification. (A) Megamix-Plus side-scatter (SSC) beads (polystyrene) with size references of 0.16, 0.2, 0.24, and
0.5µm were applied to define a flow cytometric SSC-based gate for microvesicles (MVs) (defined as lipid vesicles). Lipid vesicle equivalents (eq) of the indicated sizes
were estimated, taking the different refractive indices of polystyrene and lipid vesicles into account. Gate 1 contains TruCount beads used for quantification of MVs.
Gate 2 corresponds to the MV gate used throughout the study. For comparison, normal platelets stained with anti-CD61 antibody were added to the sample (gray
events). (B) Forward-scatter (FSC)/SSC characteristics of MVs isolated from culture supernatants and stained with calcein (gray events). (C) MVs contained in culture
supernatants from peripheral blood mononuclear cells (PBMCs) incubated with the TLR9-agonist ODN2395. The MVs were incubated with calcein and anti-G3BP
antibody (gray) or isotype control (black). (D) Corresponding histogram after staining with anti-dsDNA antibody (gray) or isotype control (black). (E) Contour plot of
MVs released from non-stimulated PBMCs and stained for G3BP (x-axis) and dsDNA (y-axis). (F) Corresponding contour plot of MVs released from PBMCs stimulated
with ODN2395. Events within gate 2 are shown in (C) through (F).
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FIGURE 2 | Presence of microvesicles in culture supernatant. Microvesicles (MVs) in culture supernatant from ODN2395-stimulated peripheral blood mononuclear
cells were visualized by means of transmission electron microscopy using the negative stain principle. Arrows indicate round-shaped particles within the size range of
MVs as indicated by the scale bars in the lower right corners.
the background (non-stimulated controls) was subtracted, the
test was used to assess if the net values differed from zero. The
statistical analysis was performed in GraphPad Prism software
8 (GraphPad Software Inc., San Diego, USA). P < 0.05 were
considered statistically significant.
RESULTS
Flow Cytometric Measurement of MVs
MVs isolated from a total of 12 healthy donors [10 women
and 2 men, median age 26 years (range 22–63)] were analyzed
using the flow cytometry gating shown in Figure 1. TruCount
beads (Figures 1A,B, gate 1) were used for quantification and
Megamix-Plus SSC beads (0.16, 0.2, 0.24, and 0.5µm) were
used as size reference to define the MV gate (Figures 1A,B,
gate 2). Normal platelets (Figure 1A, gray events) of ∼2–
3µm in diameter (34) served to validate the estimated lipid
vesicle equivalents. In agreement with the predictions, the
SSC light of platelets showed considerable overlap with the
0.5µm bead population (Figure 1A, y-axis). The majority of
detectable calcein-positive events in the differentially centrifuged
culture supernatants (Figure 1B, gate 2, gray events) localize
within the predicted MV gate, supporting that most of these
events are in the size range of MVs. Treatment of culture
supernatants with detergent (1% Triton X-100) prior to isolation
of MVs abolished the signal from calcein, confirming the lipid
nature of calcein-positive events (Supplementary Figure 2A).
Moreover, MVs were only detectable in supernatants from
setups containing added PBMCs, confirming that the signal
from calcein within the MV gate is derived completely from
the experimental cells and not from artifacts or residual MVs
potentially present in the hFCS (Supplementary Figure 2B). We
also evaluated the MV assay for coincident events which might
cause false colocalization signals, but such phenomenon was not
observed (Supplementary Figure 2C).
Identification of MVs With Transmission
Electron Microscopy
The presence of MVs in culture supernatants was confirmed
by use of transmission electron microscopy. Specifically,
culture supernatants from ODN2395-stimulated PBMCs were
investigated; round-shaped particles within the MV-size range
were identified, showing the presence of MVs in these
supernatants (Figure 2).
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FIGURE 3 | Release of G3BP- and/or dsDNA-expressing microvesicles from peripheral blood mononuclear cells. (A) Peripheral blood mononuclear cells from healthy
donors were incubated for 24 h with either anti-CD3 antibody (OKT3) (n = 6), the TLR3-agonist poly(A:U) (n = 6), the TLR4-agonist LPS (n = 6), the TLR7-agonist
gardiquimod (n = 6), or the TLR9-agonist ODN2395 (n = 6), or were treated with staurosporine (STS) to induce apoptosis (n = 6). Microvesicles (MVs) released into
the culture supernatants were subsequently isolated by differential centrifugation. Isolated MVs were quantified and characterized with respect to expression of G3BP
and dsDNA by flow cytometry. The change in the concentration of MVs in culture supernatants, induced by the various stimuli, is shown. Columns and error bars
represent median values and interquartile range after subtraction of background (non-stimulated controls). (B) Corresponding quantifications of G3BP and dsDNA
double-positive MVs. (C) Changes in the concentration of the G3BP-expressing MV population in toto. (D) The fold change in the concentration of G3BP-expressing
MVs, expressed as the ratio of MV count in stimulated samples over that of non-stimulated samples (NS). (E) Changes in the concentrations of the dsDNA-expressing
MV population in toto. (F) The fold change in the concentration of dsDNA-expressing MVs. *P < 0.05. NS, non-stimulated.
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FIGURE 4 | Effect of T cell stimulation on release of microvesicles from peripheral blood mononuclear cells. Peripheral blood mononuclear cells from healthy donors (n
= 7) were incubated for 24 h with the TLR9-agonist ODN2395 in presence or absence of anti-CD3 antibody (OKT3). Microvesicles (MVs) released into the culture
supernatants were subsequently isolated by differential centrifugation. Isolated MVs were quantified and characterized with respect to expression of G3BP and dsDNA
by flow cytometry. (A) Concentration of MVs expressing G3BP (white columns), dsDNA (gray columns), or both (black columns) after subtraction of concentrations
observed in non-stimulated cultures. (B) The corresponding fold change, expressed as the ratio between G3BP-expressing MVs in supernatants from stimulated and
non-stimulated cultures (NS). (C) The corresponding fold change in the dsDNA-expressing MV population. Columns and error bars represent median values and
interquartile range. *P < 0.05. NS, non-stimulated.
FIGURE 5 | Effect of different TLR9-agonists on release of microvesicles from peripheral blood mononuclear cells. Peripheral blood mononuclear cells from healthy
donors (n = 7) were incubated for 24 h with ODN2006, a weak inducer of IFN-α, or ODN2395, a strong inducer of IFN-α. Microvesicles (MVs) released into the culture
supernatants were subsequently isolated by differential centrifugation. Isolated MVs were quantified and characterized with respect to expression of G3BP and dsDNA
by flow cytometry. (A) Shown is the consequent increase in the concentration of MVs expressing G3BP (white columns), dsDNA (gray columns), or both (black
columns). (B) The concentration of G3BP-expressing MVs in cultures of stimulated cells relative to that in non-stimulated cultures (NS). (C) The corresponding relative
concentration of dsDNA-expressing MVs. Columns and error bars represent median values and interquartile range. *P < 0.05. NS, non-stimulated.
TLR-Mediated Release of dsDNA- and
G3BP-Expressing MVs From Mononuclear
Cells
Stimulation of PBMCs with the TLR9-agonist ODN2395
lead to release of MVs with distinct expression of G3BP
(Figure 1C) and surface-bound dsDNA (Figure 1D) into the
culture supernatants. Notably, about 1/3 of MVs present in
supernatants from unstimulated PBMCs bore dsDNA but not
G3BP (Figure 1E). Stimulation with ODN2395 induced co-
expression of G3BP (Figure 1F).
We stimulated PBMCs with a series of TLR-agonists or
the T cell activating antibody OKT3, or induced apoptosis by
incubation with staurosporine (Figure 3). None of the stimuli
significantly affected the total number of MVs released, as shown
in Figure 3A, where the number of MVs in non-stimulated
cultures have been subtracted (allowing occurrence of negative
values). However, as the only stimulus, ODN2395 induced
a significant increase in the number of G3BP and dsDNA
double-positive MVs (Figure 3B) and, accordingly, in the total
number of G3BP-expressing MVs (Figure 3C). The content of
G3BP-expressing MVs was thus a median of four times higher
in OD2395-stimulated cultures than in non-stimulated cultures
(Figure 3D). None of the other stimuli examined affected the
release of G3BP-expressing MVs.
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FIGURE 6 | Effect of IFN-α inhibition on TLR9-induced release of microvesicles from peripheral blood mononuclear cells. Peripheral blood mononuclear cells from
healthy donors (n = 6) were incubated for 24 h with the TLR9-agonist ODN2395, alone (–) or in combination with the IFN-α inhibitor IFN alpha-IFNAR-IN-1
hydrochloride (+). Released microvesicles (MVs) were quantified, and expression of G3BP and dsDNA by the MVs was analyzed by flow cytometry. (A) Concentration
in the culture supernatant of the total MV population and (B) subpopulations of G3BP-expressing, dsDNA-expressing, and G3BP and dsDNA double-positive MVs.
(C) Corresponding concentration of the total MV population and (D) subpopulations after co-stimulation of T cells with anti-CD3 antibody. *P < 0.05.
Stimulation with ODN2395 induced a non-significant
increase in the number of dsDNA-expressing vesicles released
into the supernatant (Figures 3E,F). Specificity of the staining
for dsDNA was confirmed by the observation that preincubation
of culture supernatants from ODN2395-treated PBMCs
with DNase markedly reduced the binding of the detecting
anti-dsDNA antibody to MVs (data not shown).
Influence of T Cells on TLR9-Mediated
Release of MVs
As indicated above, cross-binding of CD3 on T cells per se did
not influence MV release from mononuclear cells. To investigate
whether cross-binding of CD3 had any influence on the TLR9-
mediated MV release, we stimulated PBMCs with ODN2395
alone or in combination with anti-CD3 antibody (Figure 4).
The co-stimulation markedly enhanced the ODN2395-induced
release of G3BP-expressing MVs in toto and of G3BP and
dsDNA double-positive MVs (Figures 4A,B), whereas the
release of dsDNA-expressing MVs in toto was not affected
significantly (Figures 4A,C).
Effect of Different TLR9-Agonists on MV
Release and Phenotype
Since ODN2395 is a potent inducer of IFN-α, we examined
how the effect of another TLR9-agonist, ODN2006, which is
known to be a weak IFN-α-inducer (23), affected MV release
and phenotype studied. Notably, ODN2006 was a much weaker
stimulus for release of G3BP-expressing MVs than ODN2395
(Figures 5A,B), suggesting that acquisition of this phenotype
depended, at least in part, on secretion of IFN-α. The release
of dsDNA-expressing MVs in toto did not differ significantly
between the two stimuli (Figures 5A,C).
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Effect of IFN-α Inhibition on TLR9-Induced
Release of MVs
To test directly if IFN-α was involved in generation of
G3BP- or dsDNA-expressing MVs, we employed the IFN-α
inhibitor IN-1 (Figure 6). Despite having little effect on the
overall release of MVs from PBMCs stimulated with ODN2395
(Figure 6A), this inhibitor significantly reduced the release of
G3BP-expressing MVs (Figure 6B). A similar effect pattern was
observed after co-stimulation of the PBMCs with anti-CD3
antibody (Figures 6C,D), but in this situation the release of
dsDNA- and double-positive MVs was also reduced significantly
by IN-1 (Figure 6D).
DISCUSSION
The purpose of this study was to investigate the mechanisms
underlying release of MVs from normal mononuclear cells, and
to characterize the released MVs with respect to expression of
dsDNA and G3BP. Insight into these mechanisms may enhance
our understanding of MV release, in general, and, since G3BP-
expressing MVs may deposit on the GBM, it may also help to
understand how nephritis develops in SLE (35).
Our main finding was that incubation of PBMCs with the
TLR9-agonist ODN2395 caused qualitative changes in MVs
released from cultivated PBMCs, while the total number of MVs
released were largely unchanged. Thus, ODN2395 induced a
substantially increased co-expression of G3BP and dsDNA on
the MV surface. A surface-localized signal from both the former
and latter is supported by the vesicles’ ability to retain calcein,
suggesting low vesicular permeability. By contrast, the TLR3-
agonist poly(A:U), the TLR4-agonist LPS and the TLR7-agonist
gardiquimod had no effect on the total MV release, nor on the
MV phenotypes studied. TLR9 binds hypomethylated CpG-rich
DNA (36), suggesting that ICs containing such DNA may be
a physiological stimulus for release of G3BP-expressing MVs.
However, the TLR9-agonist ODN2006 did not induce release of
G3BP-expressing MVs. This discrepancy may be related to the
ability of ODN2395 to induce production of IFN-α in contrast
to ODN2006 (23). In accordance with this notion, we observed
a marked reduction in the frequency of G3BP-expressing MVs
in presence of the IFN-α inhibitor IN-1. The enhancement of
MV expression of G3BP by IFN-α may be relevant to SLE
pathogenesis, in light of the exaggerated production of IFN-α by
plasmacytoid dendritic cells (pDCs) in this disease (20).
In contrast with the markedly increased G3BP-expression by
MVs after stimulation with ODN2395, this TLR-agonist had little
effect on the expression of dsDNA by the MVs; nor was this
expression differentially regulated by the two TLR9-agonists used
in this study.
To examine the effect of T cell stimulation on MV-production
and phenotype, we included an anti-CD3 antibody as stimulus.
Interestingly, this stimulus markedly enhanced the ODN2395-
induced generation of G3BP-expressing MVs and of G3BP and
dsDNA double-positive MVs. These effects of T cells may rely
on cytokine production by the T cells, in keeping with previous
findings that in-vitro activated T cells from healthy donors
and SLE patients enhance the secretion of IFN-α from pDCs
stimulated with the TLR9-agonist ODN2216 (22). However,
T cell TLR9 and the T cell receptor (with CD3 as co-receptor)
have previously been demonstrated to act in concert (37) and we
cannot exclude that the increased number of G3BP-expressing
MVs released following co-stimulation via CD3 originate from
T cells per se. We have previously shown that a significant
proportion of MVs isolated from the blood of healthy donors and
SLE patients express CD3, indicating that they have been released
by T cells (38).
G3BP has been shown to bind to several proteins, including
collagen IV, nidogen, and fibronectin (19), all of which have
been demonstrated in the GBM. It also binds to galectin-
1 and galectin-3 with high affinity (39), and both these
galectins are expressed by many immune cells, including T
cells, B cells and macrophages (40, 41). Under physiological
circumstances, expression of G3BP by MVs may therefore
serve an immunoregulatory function. Moreover, G3BP has a
scavenging function and may thus facilitate clearance of MVs
(18). In SLE, however, G3BP-expressing MVs may deposit
in kidney glomeruli, where overexpression of galectin-3 has
been observed (42). The dsDNA co-expressed by the MVs
is likely to become target for anti-dsDNA antibodies and
complement activation may ensue. To this end, bound IgG (12)
and complement fragments (38) have been demonstrated on
circulating MVs from SLE patients. It has thus been speculated
that G3BP and dsDNA double-positive MVs may deposit in
the GBM and contribute to the kidney damage observed in
SLE (8).
In conclusion, we show that stimulation through TLR9 induce
G3BP-expression of MVs released from healthy donor PBMCs in
an IFN-α-dependent manner, and that a substantial proportion
of the MVs co-express dsDNA. The excessive production of
IFN-α and anti-dsDNA antibodies in SLE and overexpression
of galectin-3 in the patients’ kidney glomeruli suggest that
G3BP and dsDNA co-expressing MVs hold a strong pathogenic
potential in this disease.
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